ESSEX BIO-TECH (01061) rose nearly 9% in the afternoon session. As of the time of writing, the stock was up 5.83%, trading at HK$4.36, with a turnover of HK$5.2576 million. The company recently announced that the Group will exhibit at the 2026 Asia-Pacific Academy of Ophthalmology Congress (APAO 2026), held from February 5th to 8th at the Hong Kong Convention and Exhibition Centre. The Group will prominently feature two core products: EB12-20145P (Bevacizumab) and single-dose Befushu Eye Drops. Notably, EB12-20145P continues to demonstrate strong momentum in clinical development. This project has been selected for the congress's poster presentation session, where its clinical progress and R&D insights will be showcased to the international ophthalmology community. It is also worth noting that the company recently announced that its wholly-owned subsidiary, Majeton, has entered into an exclusive distribution agreement with Osteopore. Osteopore is a global leader in 3D printed bio-mimetic and bio-resorbable implants. The collaboration with Osteopore marks a milestone for the Group in the dental market, expanding its portfolio of dental, orthodontic, and maxillofacial solutions, and is set to jointly support the Group's pursuit of sustainable growth in the Chinese market.